Stock Trade of the Week: Corcept Therapeutics (Nasdaq: CORT)
Corcept Therapeutics has doubled in price in the first 10 months in each of the last three years.
How? In 2015, during late January, the stock was trading under $3. By March, the stock was above $6.
In 2016, once again in late January, the stock was below $3.50, but was above $7 by early October.
In 2017, yet again in late January, the stock was trading around $7 and in early August the stock was trading above $14.
Obviously there is a cyclical pattern in Corcept’s stock price.
We see on the chart that in addition to the seasonal pattern, a trendline has formed that connects the lows over the past year and the stock just recently bounced off of that trendline.
You can also see that the two oscillators have dipped down to levels that have marked reversals in the last couple of years.
If you aren’t familiar with the company, Corcept Therapeutics Incorporated is a pharmaceutical company that discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States.
The company has several drugs on the market already and there are a number of drugs that are in various trial phases as well.
The company was founded in 1998 and is headquartered in Menlo Park, California.
From a fundamental perspective, CORT has performed extremely well.
The earnings per share have grown at an annual rate of 254% over the last three years and estimates are for a growth rate in the current year of 180%.
The company’s return on equity is 60% with a profit margin of 27% and an operating margin of 28%.
Sales have grown at a rate of 75% over the last three years and analysts expect the EPS and sales growth to continue.
Current estimates are for growth of 109% for the next year with annualized growth of 71% per year for the next five years.
Looking at the sentiment toward CORT, there is a bit of pessimism.
The current short interest ratio is at 5.72, meaning almost six days of average volume are sold short.
The analysts’ ratings on CORT are interesting.
There are only four analysts following the stock with one rating it a “strong buy”, one rating it a “buy”, one rating it as an “underperform” and one rating it as a “sell”.
This leaves room for upgrades as well as additional analysts following the stock.
Suggested strategy: Buy CORT with a maximum entry price of $20. I would set a target of at least $30 in the next six months (for a 50% potential return) with a secondary target of $40 (for a 100% potential return) over the next 9-12 months. I would also set a stop-loss at $15.